Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.07.016
Abstract: BACKGROUND Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or photosensitivity depending on… read more here.
Keywords: adverse events; encorafenib; columbus study; encorafenib binimetinib ... See more keywords